- Home
- GDTC vs HKPD Comparison
GDTC vs HKPD Comparison
Compare GDTC & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- HKPD
- Stock Information
- Founded
- GDTC 2018
- HKPD 2016
- Country
- GDTC Singapore
- HKPD Hong Kong
- Employees
- GDTC N/A
- HKPD N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- HKPD Other Pharmaceuticals
- Sector
- GDTC Health Care
- HKPD Health Care
- Exchange
- GDTC Nasdaq
- HKPD Nasdaq
- Market Cap
- GDTC 24.2M
- HKPD 20.9M
- IPO Year
- GDTC 2023
- HKPD 2025
- Fundamental
- Price
- GDTC $2.28
- HKPD $1.18
- Analyst Decision
- GDTC Buy
- HKPD
- Analyst Count
- GDTC 1
- HKPD 0
- Target Price
- GDTC $5.00
- HKPD N/A
- AVG Volume (30 Days)
- GDTC 105.3K
- HKPD 143.3K
- Earning Date
- GDTC 01-01-0001
- HKPD 08-14-2025
- Dividend Yield
- GDTC N/A
- HKPD N/A
- EPS Growth
- GDTC N/A
- HKPD N/A
- EPS
- GDTC N/A
- HKPD N/A
- Revenue
- GDTC $573,193.00
- HKPD $20,313,818.00
- Revenue This Year
- GDTC $5.37
- HKPD N/A
- Revenue Next Year
- GDTC N/A
- HKPD N/A
- P/E Ratio
- GDTC N/A
- HKPD N/A
- Revenue Growth
- GDTC 63.03
- HKPD 21.72
- 52 Week Low
- GDTC $1.65
- HKPD $0.81
- 52 Week High
- GDTC $4.05
- HKPD $3.79
- Technical
- Relative Strength Index (RSI)
- GDTC 61.26
- HKPD 43.49
- Support Level
- GDTC $1.95
- HKPD $1.18
- Resistance Level
- GDTC $2.43
- HKPD $1.32
- Average True Range (ATR)
- GDTC 0.18
- HKPD 0.11
- MACD
- GDTC 0.02
- HKPD -0.02
- Stochastic Oscillator
- GDTC 71.00
- HKPD 2.27
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.